International Application No. PCT/US06/03644 by University of Massachusetts has lately entered into Indian National Phase and published as Application No. 3834/CHENP/2007A for HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF. The National Phase Application is filed on September 03, 2007 claiming priority from International Application (published as WO2006/084006) filed February 02, 2005.
Friday, November 30, 2007
Legal Process Outsourcing (famously known as Legallyours) has been selected by the ABA Journal as one of the 100 best websites for lawyers, which invite readers to vote for their favorite legal blog (voting will continue until January 02, 2008). Your invaluable vote can make Legallyours the best legal blog. PatentCircle humbly requests its Readers to take out a moment from their invaluable time and vote for Legalllyours. To vote, please click on http://www.abajournal.com/blawgs/blawg100/toolkit, scroll down to about 80% of the page or search for "Rahul" and click on the vote button adjacent to the blog mention. Thanks for your support! Patent Circle
Thursday, November 29, 2007
Illinois-based healthcare company Abbott Laboratories has lately filed a National Phase Application # 1638/MUMNP/2007A for a new crystalline polymorph of Ritonavir, maturing from its PCT Application # PCT/1999/16334 published as WO 2000/004016 (the ‘016 publication) dated January 27, 2000. The National Phase Application claims its earliest priority from the US Application # 09/119,345 filed July 20, 1998. The ‘016 publication claims a crystalline polymorph (designated as Form II), a substantially pure amorphous form of Ritonavir and processes for the preparation. The crystalline Form II is obtained by treating amorphous Ritonavir with a C1-C3 alcohol, preferably anhydrous alcohol, or by recrystallization of Form I or mixtures of Form I and Form II from a solution in a suitable solvent, with seeding with Form II crystals, followed by addition of an anti-solvent. The substantially pure amorphous form is prepared from the Form I crystalline polymorph by melting Form I and rapidly cooling the melt, isolating the resulting solid provides amorphous Ritonavir, or by slowly adding a solution of Form I in a suitable solvent to an anti-solvent/water, followed by isolation of the resulting solid, or by lypophilization of a solution of Form I. The National Phase Application is divisional application of earlier filed National Phase Application # IN/PCT/2001/0018/MUMA. It seems to be that Abbott bifurcated crystalline polymorph of Ritonavir and Substantially pure amorphous Ritonavir into two applications.
Wednesday, November 28, 2007
GrantedPatent No :
Patent application Number
Title Of The Patent
"Vasoactive Intestinal Peptide Analogs"
Dabur Research Foundation
"A Process For The Preparation Of Alkyl 3-
Ranbaxy Laboratories Limited
"Oral Antispasmodic Anti-inflammatory Composition Comprising Pitofenone,
Panacea Biotec Limited
Vasoconstrictive Substituted 2,3-Dihydro-1,4 Dioxinopyridines.
Janseen Pharmaceutica N.V.
A Process For Preparing A Novel Formulation Used As A Feed Additive For Type II Diabetes
Sajan Kumar Singhania
Novel Galenic Formulations Of Meloxicam For Oral Administration
A Method For Preparing 3, 3- Disubstituted 1 -
Pharmacia & Upjohn
An Isolated Nucleic Acid Molecule Encoding A Human Nerotrophic Growth Factor
Ca N. V.
"A Process of Synthesizing High Quantities Of Human Interferon Alpha 2a Protein"
Jyoti Mukherjee, Poonam Srivastava,P
"A Pharmaceutical Composition Based
on Nanoparticles of Polymeric Michelles Containing Paclitaxel"
Dabur India Limited
"Novel Substituted 1hbenz[ De]Isoquinolin
Council of Scientific
And Industrial Research
Quinolinecarboxylic Acid Derivative or Salts Thereof
Wakunaga Pharmaceutical Co., Ltd
Composition For The
Control And Prevention of Anorectal and Colonic Diseases"
Panacea Biotec Limited
India-based Suven Life Sciences Ltd said the European Patent Office has granted patents for two of Suven's compounds (EP1523486 B1 & EP1581538 B1) TETRACYCLIC 3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, aimed at treating cognitive impairments associated with neurodegenerative disorders like Alzheimer's, Parkinson's disease and schizophrenia.
The compounds are being developed as therapeutic agents and the patents are valid until June 2022, the company said in a filing to